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Abstract
Background: The prevalence of type 2 diabetes mellitus (T2DM) in children and adolescents is increasing. This has
spurred the development and publication of clinical practice guidelines (CPGs) for the management of paediatric
T2DM. Given the long-term complications of T2DM, optimal management is important to prevent or delay these
complications. However, the quality of published CPGs has not yet been empirically evaluated.
Our objective is to systematically appraise all published CPGs for the management of T2DM in children and adolescents.
Methods: We will identify all published CPGs that address T2DM in children and adolescents through MEDLINE, Embase,
CINAHL, Trip, and the National Guideline Clearinghouse and will screen diabetes and paediatric societies and associations’
websites. Search records will be screened in duplicate for inclusion. Grey literature will be covered by systematically
searching publications of all relevant diabetes societies and associations and other health organizations for CPGs that
meet our inclusion criteria. CPGs deemed eligible for inclusion will be retrieved. Quality assessment will be conducted
using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) tool by a team of four appraisers. Scaled scores
of the AGREE II will be used to gauge the overall quality of CPGs.
Discussion: The results of this review will be disseminated through presentations at local, national, and international
conferences and publication in a peer-reviewed journal. The results of this review can help improve the reporting of
future guidelines, inform decisions of policy-makers to endorse CPGs, and affect the choice of guideline use in clinical
practice.
Systematic review registration: PROSPERO CRD42016034187
Introduction
Type 2 diabetes mellitus (T2DM) is a relatively new disease
in children, driven mainly by the obesity epidemic [1–3].
While the pathophysiology of paediatric T2DM is not
completely understood, the main drivers of its etiopatho-
genesis are related to a combination of obesity-driven
insulin resistance in the skeletal muscle, liver, and adipose
tissue [4]. This is coupled with β-cell failure to produce
sufficient insulin to overcome insulin resistance due to
inflammation, glucotoxicity, and lipotoxicity [5–10].
Paediatric T2DM patients are at risk of secondary
comorbidities including dyslipidaemia, hypertension, non-
alcoholic fatty liver disease, polycystic ovary syndrome, ob-
structive sleep apnoea, and psychological problems [11–13].
These comorbidities increase the risk for cardiovascular dis-
ease [14]. In addition, T2DM patients can develop acute
life-threatening complications including diabetic ketoacido-
sis and hyperosmolar hyperglycaemic state [15, 16].
Limited therapeutic options exist for children with
T2DM. Currently, lifestyle intervention, metformin, and
insulin are the only available therapeutic modalities, with
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other medications undergoing trials to validate their role
in children and youth [13, 17, 18].
Due to its relative novelty, there are no natural history
data to guide prognosis, and it is possible that children
with T2DM will have a shorter lifespan than their non-
diabetic counterparts, due to the association of diabetes
with cardiovascular and renal causes [19].
In response to this crisis, clinical practice guidelines
(CPGs), defined as ‘systematically developed statements
to assist practitioner and patient decisions about appro-
priate healthcare for specific clinical circumstances,’ to
guide the care of children and adolescents with T2DM
have been developed [20].
The potential for CPGs to enhance the care of
children and adolescents with T2DM is dependent on
their quality, as well as uptake and adoption in practice.
High-quality, evidence-driven CPGs have the potential
to improve patient outcomes, due to their ability to
standardize the delivery of evidence-based care by a
large number of healthcare practitioners. CPGs also have
the potential to improve the allocation and utilization of
finite healthcare resources and reduce waste.
There is evidence that those CPGs in some health con-
ditions are of variable quality [21–23], and this has the
potential to impact care delivery and outcomes.
The purpose of this systematic review is to evaluate
the quality of published CPGs for management of
T2DM in children and adolescents and to evaluate the
changes in their quality over time.
Research question
Do CPGs of paediatric type 2 diabetes mellitus conform
to quality standards based on the AGREE II tool? If so,
has the quality of these guidelines changed over time?
Objectives
Primary The primary objective of this systematic review
is to evaluate the quality of published CPGs for the man-
agement of T2DM in children and adolescents using the
Appraisal of Guidelines for Research and Evaluation II
(AGREE II) tool.
Secondary The secondary objective of this systematic
review is to determine whether the quality of CPGs that
have been revised or updated has improved over time.
Methods
The protocol is registered with PROSPERO (registration
number: CRD42016034187). A PRISMA-P checklist is
included to report the various sections under which each
item is described (Table 1) [24, 25].
Eligibility criteria
Published national or international CPGs from diabetes
and paediatric associations that are reported as stand-
alone guidelines for T2DM in children and adolescents
(2–18 years of age) will be included. In addition, guidelines
that address type 1 diabetes mellitus (T1DM) in children
and adolescents and dedicate a section on recommenda-
tions for managing T2DM in this age group will be
screened. CPGs that are targeted to the management of
adult T2DM with a separate section with specific recom-
mendations for management of T2DM in children and
adolescents will also be included. We will compare the
two most recent guidelines from a given agency if
available and will not restrict language of publication
of the included guidelines.
Unpublished CPGs, CPGs developed for exclusive
use within one institution, and CPGs currently under
development will be excluded. We will also exclude
studies that make recommendations for management
of paediatric T2DM but are not CPGs. These include
randomized controlled trials (RCTs), including cluster
RCTs, controlled (non-randomized) clinical trials, and
case-control, prospective and retrospective cohort, and
cross-sectional studies in T2DM. We will also exclude case
reports, pilot and feasibility studies, and conference
abstracts and posters.
We will also exclude guidelines that deal with drug-
induced diabetes including steroids, antipsychotic medi-
cations, and immunomodulatory therapies or guidelines
that deal with genetic forms of diabetes, e.g. maturity-
onset diabetes of the young (MODY).
The primary outcome is the evaluation of the quality
of the guidelines by calculating the AGREE II tool score
for treatment of T2DM in children and adolescents.
The secondary outcome is to determine whether the
quality of CPGs that have been revised or updated has
improved over time.
Data sources and search strategy
The search strategy will be developed in consultation with
a health sciences librarian with expertise in systematic
reviews. We will search databases including MEDLINE
and Embase through the Ovid interface, Cumulative Index
to Nursing and Allied Health Literature (CINAHL), Trip,
and the National Guideline Clearinghouse (guideline.gov).
The search will be conducted from the inception of each
database up to and including January 31, 2016.
The search will be tailored to the capabilities of
each database. Medical Subject Headings (MeSH) and
keywords relating to (1) CPGs, (2) diabetes, and (3)
children and/or adolescents will be combined using
Boolean search operators. The search will not be limited
to T2DM in order to capture guidelines that cover both
T1DM and T2DM.
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Table 1 PRISMA-P checklist for protocol items
Section and topic Item No Checklist item Page No Line No
ADMINISTRATIVE INFORMATION
Title:
Identification 1a Identify the report as a protocol of a systematic review 1 Title
Update 1b If the protocol is for an update of a previous systematic review, identify as such N/A N/A
Registration 2 If registered, provide the name of the registry (such as PROSPERO) and registration number 2 22
Authors:
Contact 3a Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical
mailing address of corresponding author
1 -
Contributions 3b Describe contributions of protocol authors and identify the guarantor of the review 11 209–219
Amendments 4 If the protocol represents an amendment of a previously completed or published protocol,




Sources 5a Indicate sources of financial or other support for the review 11 208
Sponsor 5b Provide name for the review funder and/or sponsor 11 208
Role of sponsor or
funder
5c Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol N/A N/A
INTRODUCTION
Rationale 6 Describe the rationale for the review in the context of what is already known 3–4 24–55
Objectives 7 Provide an explicit statement of the question(s) the review will address with reference to
participants, interventions, comparators, and outcomes (PICO)
4 56–63
METHODS
Eligibility criteria 8 Specify the study characteristics (such as PICO, study design, setting, time frame) and report
characteristics (such as years considered, language, publication status) to be used as criteria
for eligibility for the review
4 56–58
4–5 69–91
Information sources 9 Describe all intended information sources (such as electronic databases, contact with study
authors, trial registers or other grey literature sources) with planned dates of coverage
6 92–114
Search strategy 10 Present draft of search strategy to be used for at least one electronic database, including
planned limits, such that it could be repeated
Table 2 Table 2
Study records:
Data management 11a Describe the mechanism(s) that will be used to manage records and data throughout the review 7 116–117
Selection process 11b State the process that will be used for selecting studies (such as two independent reviewers)




11c Describe planned method of extracting data from reports (such as piloting forms, done
independently, in duplicate), any processes for obtaining and confirming data from investigators
7 120–121
9 163–170
Data items 12 List and define all variables for which data will be sought (such as PICO items, funding sources),




13 List and define all outcomes for which data will be sought, including prioritization of main
and additional outcomes, with rationale
8 138–141
Risk of bias in
individual studies
14 Describe anticipated methods for assessing risk of bias of individual studies, including
whether this will be done at the outcome or study level, or both; state how this
information will be used in data synthesis
8–9 153–169
Data synthesis 15a Describe criteria under which study data will be quantitatively synthesised 9 171–188
15b If data are appropriate for quantitative synthesis, describe planned summary measures,
methods of handling data and methods of combining data from studies, including any
planned exploration of consistency (such as I2, Kendall’s τ)
9 171–188
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The search will be limited by age group and publication
type. The age range will be specified as 2–18 years,
effectively excluding references on gestational diabetes or
congenital forms of diabetes. The publication type will be
limited to guidelines. Table 2 presents a sample search,
which will be run on MEDLINE. The search strategy may
be revised to enhance sensitivity and specificity.
To identify guidelines published outside of indexed jour-
nals, our search of key databases will be supplemented
with a search of the grey literature. This will be covered
by systematically searching publications of all relevant dia-
betes societies and associations and other health organiza-
tions for CPGs that meet our inclusion criteria.
The world will be divided into the Americas (North and
South), Europe, Asia (including Australasia and Oceania),
and Africa. Four reviewers will be tasked with systematic-
ally searching online for relevant CPGs published by
diabetes societies and associations and other medical and
health organizations in their assigned regions.
Data management
Search results will be uploaded to a private group on
Mendeley (https://www.mendeley.com), a reference man-
agement tool. Exact duplicates will be removed.
Data selection process
Two independent reviewers will screen titles and ab-
stracts of records on Mendeley, and those deemed eli-
gible for inclusion will be retrieved and uploaded onto
an external database. Retrieved eligible records will
undergo duplicate full-text screening for inclusion. Rea-
sons for exclusion will be documented and reported.
Disagreements between reviewers will be resolved by
discussion or by consulting an expert paediatric endo-
crinologist (MCS). The team has been educated on the
subject area by an expert clinician and researcher (MCS)
to ensure familiarity with the research field.
Data items
For data extraction protocol, we will include the title,
authors, issuing society/association, country, year of publi-
cation or update, criteria and frequency of screening for
T2DM, screening test(s) recommended, and diagnostic
criteria. We will also include recommendation of health-
care delivery including personnel needed and recommen-
dations on physical activity, diet, screen time, psychosocial
issues, medical and surgical therapies, target HbA1c, and
screening methods and frequency for comorbidities
including nephropathy, retinopathy, hypertension, dyslip-
idemia, non-alcoholic fatty liver disease, neuropathy, and
polycystic ovary syndrome.
Outcomes and prioritization
The primary outcome is the score of the AGREE II
guideline. The secondary outcome is the demonstration
of improvement in score over time for those agencies
that have updated versions of their guidelines.
Table 1 PRISMA-P checklist for protocol items (Continued)
15c Describe any proposed additional analyses (such as sensitivity or subgroup analyses,
meta-regression)
N/A N/A
15d If quantitative synthesis is not appropriate, describe the type of summary planned 10 184–188
Meta-bias(es) 16 Specify any planned assessment of meta-bias(es) (such as publication bias across studies,




17 Describe how the strength of the body of evidence will be assessed (such as GRADE) 9 178–179
Table 2 Sample search conducted on MEDLINE using the OVID
interface
# Searches
1 guideline/ or practice guideline/
2 guideline*.ti,ab,kf.
3 guideline.pt.
4 Consensus Development Conference/
5 consensus statement*.ti,ab,kf.
6 or/1–5





11 (T1DM or T2DM or T1D or T2D).ti,ab,kf.
12 ((noninsulin or non insulin or insulin) adj2 depend*).ti,ab,kf.
13 or/7–12








15 6 and 13 and 21
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Quality appraisal
CPGs deemed eligible for inclusion will be appraised using
the AGREE II [26]. The AGREE II is a generic instrument
developed for quality evaluation of health-related CPGs. It
evaluates the process of guideline development and report-
ing across six domains (scope and purpose, stakeholder
involvement, rigour of development, clarity of presentation,
editorial independence, and applicability) using a seven-
point Likert scale (whereby seven indicates the highest
quality). The instrument also contains two additional
global items. The first item is on the overall assessment of
the quality of the guideline on a seven-point Likert scale,
and the second item is on whether the guideline can be
recommended for use, which is assessed on an ordinal
scale of ‘yes’, ‘yes with modifications’, and ‘no’.
The AGREE II instrument was chosen due to its already
widespread use and validation [26–28]. The instrument
can be used by researchers, clinicians, and policy-makers
with varying experiences in the development and use of
CPGs [26]. In user-testing, the instrument has shown
acceptable reliability and construct validity, with statisti-
cally significant (p < 0.05) differences found in the scores
of high- and low-quality guidelines of all but three of the
23 items [27, 28]. The number of appraisers required for
an inter-rater reliability of 0.7 ranges from two to five
across domains [26]. Although only two of the domains
achieved an alpha value that met conventionally ac-
cepted standards for internal consistency (Cronbach’s
alpha ≥ 0.8), this could be attributed to the small
number of items in each domain (range 2–8).
A team of four appraisers will perform quality assess-
ment; this is the preferred number of appraisers necessary
to reach acceptable inter-rater reliability (intra-class cor-
relation coefficient (ICC) ≥ 0.7) on the AGREE II [26, 27].
Prior to appraisal, appraisers will complete the AGREE II
Online Training Tool (http://www.agreetrust.org/resou
rce-centre/agree-ii-training-tools/) and will participate in
at least three rounds of calibration with a sample of rele-
vant CPGs of varying qualities. Additional rounds of cali-
bration will be completed until an inter-rater reliability of
0.7 is achieved. All appraisals will be conducted using the
online My AGREE PLUS platform (http://www.agreetrust
.org/resource-centre/agree-plus/).
Data synthesis and analysis
All statistical analyses will be conducted using SPSS
Statistics Version 22.
A flow diagram (Fig. 1) will be constructed to illustrate
the flow of citations through the course of this system-
atic review.
Agreement regarding CPG eligibility between reviewers
will be reported as Cohen’s kappa. The target level of
Fig. 1 Flow chart for steps taken using the AGREE II tool for evaluation of available paediatric type 2 diabetes guidelines
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agreement will be set as 0.8, indicating strong agreement
between reviewers.
Descriptive statistics will be generated and tabulated to
summarize the characteristics of CPGs deemed eligible for
inclusion. For each CPG, a quality score will be calculated
for each of the six domains of AGREE II, using the
formula presented in the AGREE II User’s Manual [26].
Briefly, domain scores will be calculated by summing up
all the appraisers’ scores of the individual items in a
domain and by scaling the total as a percentage of the
maximum possible score for that domain. This calculation
is automatically generated on the My AGREE PLUS
platform. Inter-rater reliability between appraisers for each
domain of the AGREE II will be presented as ICCs, with a
target ICC of 0.7 for all domains. The overall quality of
the included CPGs in each domain of the AGREE II
will be presented in a table using summery statistics
(mean ± SD) for normally distributed data and medians
(minimum-maximum) for skewed distributions. As the
six domains of the AGREE II are independent, domain
quality scores will not be aggregated.
Dissemination
The results of this review will be presented at local,
national, and international conferences and published
in a peer-reviewed journal.
Discussion
With the increasing prevalence of T2DM in children
and adolescents and the burden of living with the dis-
ease, there is a critical need to ensure that the evidence
used in management of these children is of high quality.
In this systematic review, we will investigate the quality
of existing CPGs designed to manage paediatric T2DM.
Our proposed review can aid clinicians who wish to
enhance the care of children and/or adolescents with
T2DM by adopting CPGs in their practice, guideline
developers who wish to create better quality CPGs or
improve existing ones, researchers who wish to identify
knowledge gaps, and policy-makers looking to endorse
CPGs. The collation of this evidence will also help to
identify gaps in the available CPGs.
The extensive search strategy covering both indexed
and grey literature, use of multiple appraisers who will
complete training and calibration to assess the quality of
CPGs, and application of the AGREE II instrument,
which has established validity and reliability [27, 28], are
all strengths of this review and may help the delivery of
better care.
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